Zobrazeno 1 - 10
of 14
pro vyhledávání: '"11"'
Autor:
Holubekova, Veronika, Loderer, Dusan, Grendar, Marian, Mikolajcik, Peter, Kolkova, Zuzana, Turyova, Eva, Kudelova, Eva, Kalman, Michal, Marcinek, Juraj, Miklusica, Juraj, Laca, Ludovit, Lasabova, Zora
Publikováno v:
Frontiers in Oncology; 2023, p1-17, 17p
Autor:
Silvia Valtorta, Alessia Lo Dico, Isabella Raccagni, Cristina Martelli, Valentina Pieri, Paolo Rainone, Sergio Todde, Bastian Zinnhardt, Elisabetta De Bernardi, Angela Coliva, Letterio S. Politi, Thomas Viel, Andreas H. Jacobs, Rossella Galli, Luisa Ottobrini, Valentina Vaira, Rosa Maria Moresco
Publikováno v:
Frontiers in Oncology
Frontiers in oncology 11 (2021): 664149. doi:10.3389/fonc.2021.664149
info:cnr-pdr/source/autori:Valtorta S.; Lo Dico A.; Raccagni I.; Martelli C.; Pieri V.; Rainone P.; Todde S.; Zinnhardt B.; De Bernardi E.; Coliva A.; Politi L.S.; Viel T.; Jacobs A.H.; Galli R.; Ottobrini L.; Vaira V.; Moresco R.M./titolo:Imaging Metformin Efficacy as Add-On Therapy in Cells and Mouse Models of Human EGFR Glioblastoma/doi:10.3389%2Ffonc.2021.664149/rivista:Frontiers in oncology/anno:2021/pagina_da:664149/pagina_a:/intervallo_pagine:664149/volume:11
Frontiers in Oncology, Vol 11 (2021)
Frontiers in oncology 11 (2021): 664149. doi:10.3389/fonc.2021.664149
info:cnr-pdr/source/autori:Valtorta S.; Lo Dico A.; Raccagni I.; Martelli C.; Pieri V.; Rainone P.; Todde S.; Zinnhardt B.; De Bernardi E.; Coliva A.; Politi L.S.; Viel T.; Jacobs A.H.; Galli R.; Ottobrini L.; Vaira V.; Moresco R.M./titolo:Imaging Metformin Efficacy as Add-On Therapy in Cells and Mouse Models of Human EGFR Glioblastoma/doi:10.3389%2Ffonc.2021.664149/rivista:Frontiers in oncology/anno:2021/pagina_da:664149/pagina_a:/intervallo_pagine:664149/volume:11
Frontiers in Oncology, Vol 11 (2021)
Glioblastoma (GBM) is a highly aggressive tumor of the brain. Despite the efforts, response to current therapies is poor and 2-years survival rate ranging from 6-12%. Here, we evaluated the preclinical efficacy of Metformin (MET) as add-on therapy to
Publikováno v:
Frontiers in Oncology; Sep2013, Vol. 3, p1-7, 7p
Publikováno v:
Frontiers in Oncology; 5/25/2021, Vol. 11, p1-10, 10p
Publikováno v:
Frontiers in Oncology, Vol 11 (2021)
Hepatocellular carcinoma (HCC) is a unique type of liver cancer instigated by underlying liver diseases. Pre-clinical evidence suggests that HCC progression, like other cancers, could be aided by vitamin D deficiency. Vitamin D is a lipid-soluble hor
Externí odkaz:
https://doaj.org/article/f2cc0fd62130455f9d790fd1c6280fd8
Autor:
Janciauskiene, Sabina, Wrenger, Sabine, Günzel, Steffen, Gründing, Anna Ricarda, Golpon, Heiko, Welte, Tobias
Publikováno v:
Frontiers in Oncology; 2/19/2021, Vol. 11, pN.PAG-N.PAG, 10p
Publikováno v:
Frontiers in Oncology; 12/17/2019, Vol. 9, p1-9, 9p
Autor:
Marquardt, Jens U., Edlich, Frank
Publikováno v:
Frontiers in Oncology; 12/13/2019, Vol. 9, p1-9, 9p
Autor:
Zhao, Mengxiang, Zhu, Nisha, Hao, Fengyao, Song, Yuxian, Wang, Zhiyong, Ni, Yanhong, Ding, Liang
Publikováno v:
Frontiers in Oncology; 9/18/2019, p1-9, 9p
Autor:
Rui Li, Xin Zeng, Meihua Yang, Jinmei Feng, Xiaohui Xu, Liming Bao, Tingbo Ye, Xin Wang, Bingqian Xue, Yi Huang
Publikováno v:
Frontiers in Oncology, Vol 11 (2021)
Frontiers in Oncology
Frontiers in Oncology
Improvement of understanding of the safety profile and biological significance of antidiabetic agents in breast cancer (BC) progression may shed new light on minimizing the unexpected side effect of antidiabetic reagents in diabetic patients with BC.